- BofA is monitoring Hims & Hers' performance and revenue guidance, which is built around Novo Nordisk's Wegovy drug.
- Novo Nordisk offered its Wegovy drug through the platform of Hims & Hers Health, while the company also faced legal pressure from Novo Nordisk.
Hims & Hers Health partnered with Novo Nordisk to add liraglutide and Wegovy, drawing analyst scrutiny and strategic inquiries.
1 report, 0 independent
Updated Jul 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Hims & Hers Health partnered with Novo Nordisk to add liraglutide and Wegovy, drawing analyst scrutiny and strategic inquiries.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Novo Nordisk offered its Wegovy drug through the platform of Hims & Hers Health, while the company also faced legal pressure from Novo Nordisk.Also in this story
- Hims & Hers challenged Novo Nordisk's ruling regarding drug compounding.
- Hims & Hers Health has entered the generic drug market, coinciding with the expiration of Novo Nordisk's patent and the failure of a maintenance fee.
The entities involved
-
Hims & Hers Health
American telehealth company
Nothing else this week.
-
Novo Nordisk
Danish pharmaceutical company
Related events
Coverage
Newest first; wire copies grouped- Unknown outlet